ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.07
-0.51 (-2.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close21.58
Open21.69
Bid20.70 x 3000
Ask21.04 x 900
Day's Range20.70 - 21.69
52 Week Range12.77 - 32.99
Volume2,635,110
Avg. Volume2,380,450
Market Cap3.026B
Beta (3Y Monthly)3.24
PE Ratio (TTM)N/A
EPS (TTM)-1.99
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.55
Trade prices are not sourced from all markets
  • Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
    Zacks3 days ago

    Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

    Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    # ACADIA Pharmaceuticals Inc ### NASDAQ/NGS:ACAD View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderately high for ACAD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.92 billion over the last one-month into ETFs that hold ACAD are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire9 days ago

    Glancy Prongay & Murray LLP Announces Investigation On Behalf Of ACADIA Pharmaceuticals Inc. Investors (ACAD)

    Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (“ACADIA” or “the Company”) and whether the Company’s officers and directors complied with their legal obligations to the Company and its shareholders. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [NUPLAZID] had been approved too quickly, based on too little evidence that it was safe or effective. GPM’s investigation focuses on whether the Company and its directors breached any fiduciary duties owed to shareholders.

  • ACCESSWIRE10 days ago

    Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 10, 2019 / U.S. markets rose for the fourth consecutive session on Wednesday as minutes released from the Federal Reserve's meeting in December showed the Fed would ...

  • Here's Why ACADIA Pharmaceuticals Dropped 15.2% in December
    Motley Fool12 days ago

    Here's Why ACADIA Pharmaceuticals Dropped 15.2% in December

    The pharma company was an easy target for Mr. Market during last month's sell-off, but it appears well positioned for a rebound in 2019.

  • Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
    Market Realist24 days ago

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.

  • Spectrum Pharmaceuticals: Financial Overview in December
    Market Realist24 days ago

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY (year-over-year) to $79.9 million from $99.8 million. During this period, the company’s net product sales were $76.4 million, which reflected an ~13% YoY decline. During the same period, the company’s revenues from license fees and services were $3.5 million, which reflected an ~70% YoY decline.

  • Business Wirelast month

    ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 37th Annual J.P.

  • Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?
    Insider Monkeylast month

    Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?

    “Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]

  • Simply Wall St.last month

    Why ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Your Next Investment

    I've been keeping an eye on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Symantec, ACADIA Pharmaceuticals, Novavax, BBX Capital, Paychex, and US Foods Holding — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the closing of its previously announced underwritten public offering of 18,602,941 shares of its common stock, including 2,426,470 shares of common stock sold pursuant to the underwriters’ ...

  • Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
    Market Realist2 months ago

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals (ACAD) stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27. On November 27, Acadia Pharmaceuticals announced a price of $17.00 per share for an underwritten public offering of 16,176,471 shares of its common stock. Acadia Pharmaceuticals’ net revenue in the first nine months of the year amounted to $164.2 million compared to $81.3 million in the same period last year.

  • Here's Why Acadia Pharmaceuticals Is Soaring
    Motley Fool2 months ago

    Here's Why Acadia Pharmaceuticals Is Soaring

    Shares rebound after the company announces the pricing details of its common stock offering.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Loxo Oncology and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Loxo Oncology and ACADIA Pharmaceuticals were two biotech stocks sinking on Tuesday. Traders showed their concern over ACADIA pricing a public offering of ...

  • Business Wire2 months ago

    ACADIA Pharmaceuticals Prices Public Offering of Common Stock

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 16,176,471 shares of its common stock, offered at a price to the public of $17.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $275.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 2,426,470 additional shares of common stock.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Benzinga2 months ago

    The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Novavax and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Wall Street closed up on Monday as oil prices stabilized and giant tech stocks such as the FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet), ...

  • Business Wire2 months ago

    ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $200,000,000 of its common stock. BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as the joint book-running managers for the offering. ACADIA intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of its common stock.

  • A Look at Amarin Corporation’s Stock Performance Year-to-Date
    Market Realist2 months ago

    A Look at Amarin Corporation’s Stock Performance Year-to-Date

    Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ACAD earnings conference call or presentation 6-Nov-18 10:00pm GMT

    Q3 2018 ACADIA Pharmaceuticals Inc Earnings Call

  • Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
    Simply Wall St.2 months ago

    Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

    ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Read More...